{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-21-027932","form_type":"8-K","ticker":"CODX","cik":"0001692415","company_name":"Co-Diagnostics, Inc.","filed_at":"2021-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.708275+00:00","generated_at":"2026-06-28T09:18:07.927851+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Co-Diagnostics reports record Q3 revenue of $30.1M, EPS $0.38, guides FY2021 revenue $96-100M","bullets":["Revenue $30.1M, up 38% YoY; gross profit $26.8M (89.0% margin).","Net income $11.5M ($0.38 diluted EPS) vs $15.7M ($0.53) in Q3 2020.","Cash and marketable securities $83.9M, up $11.5M from June 30, 2021.","FY2021 guidance: revenue $96-100M, diluted EPS $1.07-$1.16, tax rate ~18%.","Unveiled at-home/point-of-care device; JV CoSara cleared dengue/chikungunya tests in India."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-21-027932","json":"https://secwatch.observer/filing/0001493152-21-027932.json","markdown":"https://secwatch.observer/filing/0001493152-21-027932.md","text":"https://secwatch.observer/filing/0001493152-21-027932.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1692415/000149315221027932/0001493152-21-027932-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1692415/000149315221027932/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T09:18:07.927851+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}